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Preterm infants are highly susceptible to neonatal sepsis with substantial morbidity 
and mortality. Early empiric treatment is mandatory as blood culture results take up to 
48 hours. Empirical treatment is ineffective if the wrong pathogen is targeted. 
Antimicrobial peptide IDR1018 is a novel adjuvant antimicrobial with broad activity. 
IDR1018 may synergise with common neonatal antibiotics. Antibacterial 
checkerboard assays were performed of IDR1018 and the neonatal antibiotics 
vancomycin or gentamicin against prototypical neonatal pathogens. Standard testing 
conditions used RPMI1640 + 5% Luria Bertani broth. Further, time-to-kill assays were 
performed with samples taken at 0, 2, 4 and 24 hours to determine the effectiveness 
and kinetics of the drug combination in adult human serum, and compared against 
individual antibiotics or IDR1018 only and the empiric combination of gentamicin 
and vancomycin. Synergy was observed between vancomycin and IDR1018 against 3 
clinical isolates of E. coli and 1 ATCC strain using the Fractional Inhibitory 
Concentration Index. No synergistic activity was observed in human serum IDR1018 
and vancomycin against E. coli and S. aureus. IDR1018 had minimal activity against 
the bacteria independently. IDR1018 was inactive against E. coli and S. aureus in 
human serum at the synergistic dose, suggesting that at low levels of the antimicrobial 
peptide there is a component of the serum inhibiting its activity. When the human 
serum was heat treated, synergy between IDR1018 and vancomycin against E. coli 
and S. aureus was restored. Further tests are required to find the component of the 
serum that is inhibiting activity, such as denaturing the proteins in the serum before 
repeating the time-to-kill assay, or attempting to increase the level of free IDR1018 in 
the serum by raising the IDR1018 dose.  
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Neonatal sepsis, which occurs in the first month life, causes substantial mortality and 
morbidity and accounts for approximately 1.4 million neonatal deaths worldwide 
annually (1). Although there is no universally accepted definition, sepsis is caused by 
infection with systemic inflammation which leads to organ dysfunction (2). Preterm 
infants are babies born before 37 weeks gestation, and have a greater risk of 
developing neonatal sepsis when compared with infants born full term. Neonatal 
sepsis is diagnosed by the presence of a positive blood culture, which can take up to 
48 hours to identify the causative organism/s. Patients with suspected sepsis must be 
treated with empirical antibiotic therapy as soon as possible, as for every hour that 
administration of antibiotics is delayed, mortality increases by ~7% (3). Empirical 
therapy is not always effective, for instance when the pathogen is resistant to the 
chosen antibiotic therapy (4). The combination of empirical antibiotics with other 
antimicrobial compounds such as selected antibiotics or antimicrobial peptides may 
provide a more effective, broad-spectrum treatment targeting multiple classes of 
bacteria (5). 
 
Antimicrobial peptides (AMPs) are short, usually cationic peptides that are a principal 
part of the innate host defence. AMPs have shown promise as novel adjunct therapies 
to treat bacterial infections, as they are able to combat antimicrobial resistance as well 
as have the ability to target both Gram-negative and positive bacteria (6). Endogenous 
AMPs have several limitations as therapeutics, such as intolerance to physiological 




In this thesis, I specifically examine the adjunct antimicrobial activity of the synthetic 
AMP, Innate Defence Regulator (IDR) 1018, a bovine-derived cathelicidin which has 
the ability to synergise with antibiotics to be a more effective therapy against Gram 
positive and negative bacteria (8). This peptide has not been assessed with commonly 
used neonatal antibiotics and neonatal pathogens.  
 
1.2 What is neonatal sepsis? 
According to the Sepsis-3 task-force - a meeting of 19 individuals with expertise in 
various areas such as sepsis epidemiology, clinical trials, and pathobiology - sepsis is 
defined in adults as a potentially life-threatening, dysregulated host response to 
infection and is associated with organ dysfunction (9). There is no equivalent 
consensus definition of neonatal sepsis, and at present, definitions used vary 
internationally. In principle, neonatal sepsis is a clinical syndrome that is caused by a 
bacterial, viral or fungal infection and is characterised by systemic clinical signs such 
as apnea (cessation of breathing), bradycardia (slow heart rate) and cyanosis (oxygen 
deficiency) in the first 28 days of life (2, 10, 11).  
 
Globally an estimated 22 neonates per 1000 livebirths develop neonatal sepsis, with a 
mortality rate of 11-19% (12). Developing countries see a higher rate of neonatal 
sepsis compared with developed countries (12). In a study in Thailand and Myanmar 
between 2009 to 2012, 4,480 neonates per 100,000 live births developed neonatal 
sepsis (13). In comparison, a US study in 2005 had 970 neonates per 100,000 live 
births develop neonatal sepsis (12).  
 
  
1.3 Preterm infants are more susceptible to neonatal sepsis 
Preterm infants, born before 37 weeks gestation, are categorised based on degree of 
prematurity as either moderate to late preterm (32-37 weeks gestation); very preterm 
(28-32 weeks gestation), and extremely preterm infants (<28 weeks) (14). One in ten 
babies are born preterm every year, with 1 million infants dying each year from 
preterm birth complications (15). Preterm birth may be caused by multiple 
pregnancies, infection and chronic conditions, but often no causative factors are 
identified (14). Preterm infants are more susceptible to developing neonatal sepsis, 
especially those born extremely preterm as they have a functional immune immaturity 
(16). Preterm infants also require more invasive procedures such as intubation or 
venous cannula which increases their risk of nosocomially-acquired infections.  
 
1.4 Forms of neonatal sepsis 
Neonatal sepsis can occur as either early-onset sepsis (EOS) or late-onset sepsis 
(LOS), according to whether the onset of symptoms occurs within, or after the first 72 
hours of life (11). These two forms of sepsis have different causative pathogens, at-
risk populations and outcomes. EOS is caused by intrapartum or postpartum vertical 
transmission of microorganisms from the mother to the infant (17). Streptococcus 
agalactiae (Group B streptococcus) is the most common bacteria associated with 
EOS, although Escherichia coli is the most common cause of mortality (Table 1)  (16, 
18, 19). LOS is caused by nosocomial organisms transmitted from the environment, 
caregivers and parents. Coagulase negative Staphylococci, such as Staphylococcus 
epidermidis are the most commonly isolated pathogens in LOS (16) (Table 1). LOS 




1.4.1 Early onset sepsis 
In a study conducted in Australia and New Zealand between 2002 to 2012, 
representing 10.4% and 9.8% respectively of the babies born nationally in each 
country, the overall incidence of EOS was 1.17 per 1,000 live births (20). The 
incidence and severity of infection is inversely related to gestational age (21). For 
early onset sepsis caused by group B streptococcus (GBS), incidence can be reduced 
by using intrapartum maternal antibiotic prophylaxis (22). This Australian and New 
Zealand study compared sepsis rates in 1993 to 2001 and found that the EOS rate 
caused by GBS fell from 1.43/1000 live births to 0.25/1000 respectively, and 
attributed this change to the increase in use of intrapartum antibiotics (22). Risk factors 
for EOS include gestational age, intrapartum fever, prolonged rupture of membranes, 
colonisation with GBS and lack of intrapartum antibiotic prophylaxis (23).  
 
The fetus is separated in utero from the microbial flora of its mother by the 
chorioamnotic membranes and placenta (24). Chorioamnionitis is the acute 
inflammation of the fetal membranes characterised by maternal fever, maternal 
tachycardia, uterine tenderness and purulent amniotic fluid (25). Infants whose 
mothers have chorioamnionitis are more likely to develop intrapartum EOS due to the 
inhalation or swallowing of infected amniotic fluid, as well as colonisation of the 
infant’s skin and mucous membranes from chorioamnionitis pathogens shortly after 




1.4.2 Late onset sepsis 
In a study conducted in Australia and New Zealand from 1992 to 2002, representing 
10% and 20% respectively of the babies born nationally, the overall incidence of LOS 
was 8 episodes per 1,000 births (26). The median gestational age for infected infants 
was 28 weeks, while the median age of onset was 11-13 days. Invasive procedures, 
such as prolonged intravenous access, increase the risk of developing LOS as they 
provide a portal of entry for skin colonising bacteria into the bloodstream (27), As 
such, preterm infants are much more likely to develop LOS as they require more 
frequent and invasive procedures when compared with term infants, as well as lacking 
the magnitude of maternal antibodies that term infants receive in the third trimester 
(16). Barrier functions of the infant’s skin are low in preterm infants and are more 
likely to develop bacteraemia and sepsis compared with an infant born at term (19). 
The risk of developing LOS in preterm infants can be lowered by enteral feeding with 
breast milk and by administration of probiotics (28). 
 
1.5 Gram positive pathogens are associated with EOS and LOS 
EOS and LOS are associated with an overlapping range of causative organisms, which 
differ in their frequency based on the country, type of sepsis, infant gestational age 
and whether the mother was given prophylactic antibiotic therapy for GBS (5) (Table 
1). In two Australian studies conducted between 2002-2012, 55-64% and 35-42% of 
pathogens causing EOS were Gram positive and negative respectively (18, 20). The 
most common EOS pathogens were GBS, which occurred in 37% of cases, and E.coli 
which occurred in 25% of cases (20). Another study of 1,096 infants from Switzerland 
over 4 years found that Staphylococcus aureus and E. coli were detected in 16% of 
LOS cases, while Coagulase negative staphylococci (CoNS) were involved in 40% of 
  
LOS cases (29). In this study, 78% of LOS infections were hospital acquired, while 
the remaining 22% were community acquired, and infants with hospital acquired LOS 
were born at a lower gestational age. In a study conducted between 2013 and 2017 in 
a hospital in China, Gram positive pathogens were found to be the primary organisms 
causing sepsis, with 48% and 66% of cases for EOS and LOS respectively (11). 
Among these Gram positive pathogens, CoNS were the most commonly associated 
with LOS, accounting for more than 67% of Gram positive infections (11).  In contrast, 
Gram negative pathogens accounted for 37% and 30% of all infections, with E. coli 
occurring in 45% of Gram negative LOS infections (11), with Gram positive 
















Table 1.1 - Distribution of pathogens among preterm infants with EOS and LOS 
[Table extracted from (23, 30)] 
Classification Organism % of EOS cases % of LOS cases 
Gram positive CoNS 17.2 55 
 Group B Streptococcus 9.4 2 
 
Enterococci /  
Group D Streptococcus 2.8 5 
 Streptococcus viridans 6.6 0 
 Staphylococcus aureus 2.5 9 
 Listeria 3 0 
 Other 0.5 2 
Gram negative Escherichia coli 26.8 4 
 Klebsiella 6.8 4 
 Enterobacter 3.3 4 
 Pseudomonas 3 2 
 Hemophilus 4.1 0 
 Other 11.2 4 
Fungi Candida 2.8 9 




1.6  Microbiological diagnosis of neonatal sepsis  
Microbiological blood cultures are the diagnostic ‘gold standard’ for neonatal sepsis, 
although this method has several limitations (31). Available blood volumes from 
neonates for culture are limited, especially from very preterm infants, and repeated 
blood draws may increase the risk of an infant requiring a blood transfusion (4). Low 
blood volumes drawn for culture can result in a low yield of bacteria, especially when 
bacterial densities are already low (<4 CFU/mL) (32). Availability of adequate blood 
volume for culture depends on the size and gestational age of the neonate, with the 
King Edward Memorial Hospital (KEMH; Perth, Western Australia) blood culture 
protocol requiring 0.5 mL of blood for infants ≤28 weeks and 1 mL of blood for infants 
>28 weeks (33). A 1 mL sample can detect a colony count of 4 CFU/mL in 63% of 
samples, whereas a 0.5 mL sample with a colony count of 1 CFU/mL is detected only 
39% of the time (4). Bacterial yields may be further decreased if the neonate has 
received antibiotics before the blood sample was collected (34). This means that blood 
cultures have a low sensitivity and inoculation of adequate blood volumes are critical 
for accurate and timely diagnosis (4). One American study showed that 55% of 
neonatal blood samples submitted for culturing were ≤ 0.5ml (35), which resulted in 
inadequate sensitivity for samples with low CFU/mL (31).  
 
False negative diagnosis can occur when the blood culture remains negative in the 
presence of bacteraemia. This could occur if there are low bacterial densities in the 
sample, especially in the context of inappropriate blood volumes or prior antimicrobial 
exposure (4). A false negative can also occur if there has been a suppression of 
bacterial growth due to previous antibiotic administration (24), which leads to a 
tendency to give antibiotics ‘in case’ there are undetectable bugs.  
  
 
False positives can occur when a blood culture contains contaminants and causes a 
positive reading, despite the fact that the neonate does not have bacteraemia. As sepsis 
is often caused by ubiquitous commensal bacteria, contamination of blood samples by 
clinical staff can occur (36). This can especially occur when classic hand hygiene 
protocols are not followed, or due to the technical challenges of axenic blood sampling 
from a very small, moving baby in an incubator. If a false positive result occurs, 
unnecessary antibiotic therapies may possibly be administered until a correct 
diagnosis is made, which is associated with increasing healthcare costs and longer 
hospital stays as well as adverse effects from the antibiotic treatment (37).  
 
Timely identification of the causative pathogen in neonatal sepsis is also difficult due 
to the small blood volumes and low densities, with culture results taking up to 24 hours 
for Gram negative pathogens, up to 48 hours for Gram positive pathogens for a 
confirmative diagnosis and a further 24 hours to determine antibiotic sensitivities  (32, 
38). Consequently, blood cultures are limited by a lack of sensitivity and time to 
positivity. 
 
1.7 Empirical antibiotic therapy in neonates 
Newborns will be treated based on gestation, age at onset, predominant local 
pathogens and other clinical risk factors. If blood cultures are negative in a neonate 
who is seen to be clinically stable, antibiotics can be stopped at 48-72 hours (27). 
However, as outlined in Section 1.4, blood cultures have several limitations which 
mean the causative pathogen is often not known at the early stages of clinical signs, 
and in some cases for up to 48 h in infants who remain ill. In these cases, appropriate 
  
empirical antibiotic therapy must be commenced immediately due to the high level of 
mortality and morbidity of neonatal sepsis (17). 
 
Empirical antibiotic therapy in neonates is defined as early administration of 
antimicrobial therapies before the result of blood culture susceptibility (17). This 
treatment should be directed by the patterns of antimicrobial resistance of pathogens 
that are commonly detected in the Neonatal Intensive Care Unit (NICU) and 
community settings (1). The World Health Organisation provides guidelines for the 
treatment of neonatal sepsis in the Pocket book of hospital care for children (39), 
which recommends gentamicin and benzylpenicillin or ampicillin be given for >7-10 
days if sepsis is suspected or vancomycin, ampicillin and an aminoglycoside (27, 40). 
The guidelines for empirical therapy differ between infants with EOS or LOS and 














Table 1.2: Commonly used antibiotics in developed vs undeveloped countries 
Country Type of 
Sepsis 
































Empirical treatment is only necessary when the causative pathogen is unknown. Once 
the pathogen has been isolated and identified, pathogen-targeted therapy can be used. 
This is especially important as the intensive use of broad spectrum antibiotics can 
cause adverse effects, including increasing drug resistance in sepsis causing bacteria 
and the increased risk of fungal infections (42). 
 
1.7.1 Empirical antibiotic therapy for preterm infants with LOS 
KEMH guidelines call for gentamicin and vancomycin to be used as empirical therapy 
for LOS (33), therefore this study and the remainder of the literature review will focus 
on the use of gentamicin and vancomycin for LOS. 
 
  
1.7.2 Gentamicin  
Gentamicin belongs to a class of antibiotics called aminoglycosides and is derived 
from the fermentation of a Gram positive bacterium called Micromonospora purpurea 
(43). It has a chemical structure comprised of a 4,6-di-substituted deoxystreptamine 
ring (Figure 1.1). Aminoglycosides are defined as effective, broad spectrum 
multifunctional hydrophilic sugars which are bactericidal through the inhibition of 
protein synthesis (43, 44). This class of antibiotics is only able to work against Gram 
negative bacteria, such as E. coli and Klebsiella spp, as active electron transport is 
required for uptake of the drug into the cells (43).  
 
Figure 1.1: Structure of Gentamicin (43) 
 
Gentamicin inhibits protein biosynthesis, specifically by inhibiting the incorporation 
of phenylalanine, as determined experimentally using C14 labelled phenylalanine, into 
bacterial proteins (45). Gentamicin binds on the 16S ribosomal RNA of the 30S 
ribosome (44) leading to mistranslation when codon misreading occurs upon delivery 
of the aminoacyl transfer RNA (43). This process results in synthesis of a protein with 
incorrectly coded amino acids, which has the potential to cause damage to the bacterial 
cell membrane (46). Aminoglycosides are also very potent against the members of the 
Enterobacteriaceae family (45). A study of Gram negative organisms isolated from 
adult patients in intensive care units from 2009-2012 in the USA and EU, found 88% 
  
of US E. coli isolates were susceptible to gentamicin and 87% of EU E. coli isolates 
were susceptible to gentamicin according to standard laboratory testing criteria (47). 
Aminoglycosides are inactive against most  Enterococcus spp and Streptococcus spp 
(43).  
 
Entry of gentamicin into bacteria occurs in 3 different stages. During the first stage, 
permeability of the membrane of the target bacteria is increased passively (43). The 
polycationic aminoglycoside binds electrostatically to the negatively charged 
components of membrane of the bacteria (48). Gram positive organisms contain 
phospholipids and teichoic acids in the bacterial membrane that the drug binds to, 
whereas the phospholipids and lipopolysaccharide of the outer membrane are targeted 
in Gram negative organisms (46). The removal of these components through binding 
to the aminoglycoside leads to disruption of the outer membrane and aminoglycoside 
can subsequently be taken up by the cell (43). This event allows entry into the 
cytoplasm of the cell by a slow, active, electron transport mediated process (43). Once 
inside the cytoplasm, the inhibition of protein synthesis and mistranslation of proteins 
as described above can then occur. These newly created, mistranslated proteins insert 
themselves into the cytoplasmic membrane and damage the membrane which further 
increases aminoglycoside entry (49). This increase in aminoglycoside leads to more 
rapid, increased inhibition of protein synthesis, mistranslated peptides and eventually 
cell death (48).  
 
Gentamicin can cause toxicity in humans at high doses, especially ototoxicity and 
nephrotoxicity (50). To reduce the likelihood of toxicity, KEMH guidelines require 
that serum levels are monitored during therapy. Gentamicin trough levels that are >2 
  
µg/mL and peak levels that are >10 µg/mL are more likely to cause toxicity (50). 
Repeat courses of gentamicin and long-time (>10 days) exposure with trough 
concentrations of >2 µg/mL cause an increase in risk of toxicity (50).  
 
1.7.3 Vancomycin 
Vancomycin belongs to the glycopeptide class of antibiotics and was originally 
obtained from Streptococcus orientalis (51). The glycopeptide class of antibiotics is 
only effective against Gram positive aerobic bacteria. Glycopeptide antibiotics are 
large molecules that inhibit the second stage cell wall peptidoglycan synthesis of Gram 
positive bacteria (52) and are selectively toxic as the structure contains a highly 
specific cleft, which is exclusively found in bacterial cell walls (52). These peptides 
act as substrate binders, instead of active site enzyme inhibitors like other antibiotic 
classes such as penicillin (53). Glycopeptides differ based on the sugar moieties 
attached to the heptapeptide peptide core (Figure 1.2) with vancomycin containing a 
disaccharide at the fourth amino acid residue (54). Bacterial cell walls are a rigid 
polymer of peptidoglycan cross-linked by short peptides and peptidoglycan synthesis 
occurs in the cytoplasm. These monomers become assembled into the cross linked 















Figure 1.2: Chemical structure of vancomycin showing heptapeptide core and 
sugar disaccharide at 4th amino acid residue, adapted from (54) 
 
Vancomycin inhibits late-stage peptidoglycan biosynthesis by the binding of the drug 
to the d-alanyl-d-alanine carboxyl C terminus of the cell wall (55). The inhibition of 
this cross-linkage reaction results in lipid intermediates accumulating in the 
biosynthetic pathway (52). Notably, vancomycin does not need to enter the cell to 
exert its antibiotic effects.  
 
Vancomycin is used as an empirical treatment for LOS, specifically to treat Gram 
positive infections including Methicillin-resistant S. aureus, as well as CoNS species 
(56). Like gentamicin, high plasma levels of vancomycin are associated with 
ototoxicity and nephrotoxicity (57). Drug guidelines for vancomycin administration 
Sugar disaccharide  
4th amino acid 
Heptapeptide core 
  
at KEMH recommend that the total daily dose does not exceed 80 mg/kg and trough 
levels do not exceed 25 mg/L (57). Checking renal function if the trough levels are 
greater than 20 mg/L is also recommended (57). Administration of vancomycin in 
conjunction with other nephrotoxic medications such as gentamicin increases the risk 
of damaging renal function (57). 
 
1.8 The consequences of inappropriate use of antibiotics 
Antibiotics are the most commonly used medication for preterm infants in NICUs (58) 
with a large proportion of preterm infants receiving empirical antibiotics during the 
first 72 hours of life, despite the incidence of EOS being low (59). In a 2003 study 
(60), 743 extremely-low-birth-weight infants with a gestational age of <36 weeks, 
were suspected with EOS but 695 tested negative for sepsis, and 60% of these infants 
treated with long course empiric antibiotics. It was found that higher rates of mortality 
were correlated with a long course (given for ≥7 days) of antibiotic administration. 
Unnecessary long term antibiotic administration can have adverse consequences such 
as candidiasis, as the initial gastrointestinal colonisation of healthy bacteria occurs in 
the first few weeks of life, which is effected by antibiotic treatment (42, 61). Although 
an infant may have a negative blood culture for bacteraemia, vague clinical symptoms 
of sepsis makes clinicians less likely to withhold antibiotic therapy from sick infants 
(62). Prolonged and unnecessary antibiotic therapy can cause the development of 




1.8.1 Antimicrobial resistance  
Antimicrobial resistance is initiated by the overuse of antibiotics that drives the 
evolution of resistance, with a direct link between the consumption of antibiotics and 
the emergence of bacterial strains that are resistance to multiple antibiotics (63). The 
inappropriate prescription of antibiotics is a major contributing factor to antimicrobial 
resistance, with treatment indication, choice of antimicrobial or the duration of the 
treatment being incorrect in 30-50% of studied cases (64, 65). Concentrations of 
antibiotics that are sub-inhibitory are likely to promote the development of antibiotic 
resistance (63), as the highly drug sensitive bacteria die, leaving the more resistant 
bacteria to reproduce. Gentamicin and vancomycin are toxic at high concentrations, 
so it is difficult to find a dose high enough to prevent the development of resistance 
without causing harm to the patient. Gram negative sepsis contributes more to neonatal 
morbidity due to their innate resistance to antibiotics as well as their unique ability to 
develop resistance through new mechanisms transferred from other pathogens (59). In 
a study conducted in England and Wales between 2006 and 2008, up to 31% of sepsis 
isolates were resistant to the chosen drug combination for late-onset sepsis and up to 
6% of isolates for early onset sepsis.  
 
Gentamicin resistance in Gram negative bacteria occurs through many pathways, such 
as the use of efflux pumps which expel aminoglycosides from the bacterial cell or the 
natural barrier of the cell wall itself which prevents aminoglycosides from affecting 
the cell (66, 67). There are two mechanisms of resistance in bacterial ribosomes to 
evade inhibition of the aminoglycosides, with mutations of the ribosome itself or 
enzymatic modification of the ribosomes (66). Gene mutations can also occur in Gram 
negative bacteria, such as the mutant A1408G which disrupts the bond between 
  
aminoglycosides like gentamicin, and the h44 nucleotide A1408 (68). Modification or 
mutations of the bacteria species is also common, with the aminoglycosides binding 
site being modified enzymatically by 16S ribosomal RNA methyltransferases 
(RMTases). These are transferred from other species of bacteria by the uptake of a 
plasmid which contains the RMTase gene (66). RMTase genes methylate a nucleotide 
in the gentamicin binding site at the N7 position of the nucleotide G1405 in Gram 
negative bacteria. (69). 
 
A vancomycin resistant operon causes resistance to glycopeptides in species of 
Enterococcus, with the operon carried on a plasmid that encodes enzymes for the 
synthesis of low-affinity precursors (70, 71). The operon contains a response 
regulator; vanS-vanR, a d-lactate dehydrogenase gene; vanH, a d-Ala-d-Ala 
dipeptidase gene; vanX, and a ligase which has 9 variants (70, 71). The operons modify 
the vancomycin-binding target and eliminate the high-affinity precursors which are 
usually produced by the host bacteria, which therefore removes the drug binding site 
(70). The protein VanA-type glycopeptide resistance, which has a high level resistance 
to vancomycin is commonly associated with Enterococcus faecalis and Enterococcus 
faecium, although it was also detected in 7 cases of S. aureus in the USA during 2002-
2006  (71, 72). S. aureus has strains that are exhibiting vancomycin resistance, called 
vancomycin sensitive S. aureus (VISA) 
 
1.9 Improving empirical therapy in neonates 
1.9.1 Improved detection of infection 
There are multiple culture-independent methods for causative organism determination 
that are currently being developed. PCR is a highly sensitive, quantitative, real time 
  
amplification system which is based on the ribosomal DNA of bacteria, using a small 
sample of surgical tissue or body fluids (>100µl) (73). This method produces results 
within 30 minutes and has the ability to calculate bacterial load (74). Although this 
method is rapid, PCR is unable to test for susceptibility and cannot differentiate 
between active infection and recent past infections (27). Host biomarkers have also 
shown promise in diagnosing neonatal sepsis. These biomarkers are found in blood 
and increase as a response to infection, such as the C-reactive protein. (73). C-reactive 
proteins have a very low sensitivity to detect neonatal sepsis, and require 
measurements over several time points (75) so they are currently not a feasible 
diagnostic technique as a replacement for blood culture.  
 
1.9.2 Alternative therapies for sepsis 
Currently there is no approved drug for the treatment for sepsis in preterm neonates 
other than antibiotics and supportive care (76). Potential adjunct or alternate therapies 
include intravenous immunoglobin administration, lactoferrin, and granulocyte 











Table 1.3: Novel current/past neonatal sepsis therapies. Adapted from (76) 
Therapy Description Limitations References 
IVIG Use of intravenous 
immunoglobins to boost 
natural levels 







factors to stimulate 
innate immune function 
and limit apoptosis 
No significant survival 





glycoprotein found in 
colostrum and innate 
immune system 
Preventative agent, no effect 






Preterm neonates at risk 
of oxidative stress, 
therefore administering 
antioxidants 
No significant reduction in 
mortality, may reduce 
incidence 
(82) 
Glutamine Supplementation of 
essential amino acid, 
that is often lacking 
during metabolic stress 
No significant effect on 
mortality or major morbidities 
(83) 
 
It is clear that the therapies tested to date are ineffective as novel therapies against 
neonatal sepsis. AMPs, which contain antimicrobial and immunomodulatory 
properties represent a new solution that may effectively treat neonatal sepsis. 
 
  
1.9.3 Antimicrobial peptides as therapeutics for neonatal sepsis 
AMPs have shown promise as novel therapies for drug resistant bacterial infections, 
with potential action against both Gram negative and positive bacterial species (84). 
AMPs, which are also referred to as host defence peptides, are oligopeptides which 
are found naturally in a variety of organisms, including humans (85). These peptides 
have broad spectrum, antimicrobial activity with the ability to kill bacteria, fungi, 
viruses and unicellular protozoa (84). Several types of cells are involved in the 
synthesis of AMPs, including epithelial cells in the gastrointestinal and genitourinary 
systems as well as phagocytes and lymphocytes of the immune system (85). They are 
thought to be the first line of innate immune defence in the body, with some AMPs 
having the ability to modulate the innate immune system’s responses and promote 
pathogen clearance (86). Epithelial cells produce AMPs, and release them from barrier 
epithelia and glandular structures (87). Bacterial cells release lipopolysaccharide 
molecules due to host immunity which can induce AMP production, for example, 
HEK293 cells produce defensin when stimulated by lipopolysaccharides (85).  
 
AMPs have a rapid killing effect and can involve multiple cell targets, making them 
very efficient antimicrobials (88). AMPs are also less likely to develop antimicrobial 
resistance, as they are not inhibited by the resistance mechanisms that are currently 
hindering antibiotics and are active against multidrug resistant bacteria, such as 
Pseudomonas aeruoginosa and S. aureus (89). As these peptides have rapid 
bactericidal activity, a decreased tendency for development of antimicrobial resistance 
and broad spectrum ability, they have the potential to form the foundation for clinically 
useful antimicrobials (84, 90)  
 
  
There are several structural classes of peptides, a-helical peptides, b sheet peptides 
and extended/flexible peptides. There are a diverse number of AMPs in these classes, 
although all peptides have a positive charge and hydrophobic residues (90). This 
assists in allowing them to fold into amphiphilic conformation when they interact with 
the membranes of bacteria. The two most prominent groups of AMPs in vertebrates 
are defensins and cathelicidins, which have a large range of activities such as 
bactericidal activity, immunomodulation such as anti-infective and selective anti-
inflammatory properties, as well as preventing biofilm formation (91).  
 
Defensins are found in mammals, insects and plants, and are expressed in epithelia in 
mammals and can be induced to express higher levels in the case of inflammation or 
infection (92). Defensins are involved in antibacterial, antifungal and both immune 
and inflammatory responses. Cathelicidins are mainly found in mammals such as 
mice, bovids and humans and are stored in lysosomes of macrophages and neutrophils. 
LL-37 is the only cathelicidin found in humans and is an important part of the immune 
system with roles in immunomodulatory and inflammation responses (93).  
 
Direct killing occurs when cathelicidins target the cytoplasmic membranes of the 
Gram-positive and Gram-negative bacteria, which contains teichoic acid and 
phospholipids, phosphatidylglycerol, cardiolipin and phosphatidylserine that have 
negatively charged heads, causing strong electrostatic attraction to occur with cationic 
cathelicidins (Figure 1.3) (86). The structure of the outer layer of bacterial cells is 
significantly different than the outer layer of multicellular animals. The outer layer of 
animal cell membranes has a neutral net charge due to the zwitterionic phospholipid 
structure, with the majority of the negatively charged head groups facing inward 
  
towards the cytoplasm (86). This difference in structure allows the cathelicidin to only 
target bacterial cells. As Gram negative bacteria have a thick outer membrane, it has 
been proposed that AMPs are transported by self-promoted uptake by displacing ions 





Figure 1.3: Initial interaction AMPs with vertebrate compared with bacterial 
membrane prior to direct killing- extracted from (90) 
 
Many endogenous cathelicidins are intolerant to salt and are inactivated in its presence 
(7), and there is a lack of evidence for in vivo AMP efficacy in animal models (95). 
These limitations make endogenous cathelicidins difficult to use as a therapeutic 
option, however synthetic antimicrobial peptides may present the answer.  
 
  
1.9.4 IDR1018 is a potent synthetic antimicrobial peptide with therapeutic 
possibilities 
IDR1018 is a synthetic AMP derived from the bovine cathelicidin, bactenecin 
derivative, Bac2a and has an effect on the induction of macrophages which protect the 
body against infection (8). IDR1018 was generated by using the original Bac2a 
sequence as a template and using scrambling, deletions and point substitutions to 
increase the stimulation of chemokine (MCP-1) production from human macrophages 
(8). When compared with parent Bac2a peptide, and similar human peptide LL-37, 
IDR1018 had a >50-fold increase in the stimulation of MCP-1.  
 
IDR1018 is a promising antimicrobial therapeutic candidate, due to its ability to 
differentiate macrophages and promote cytokine production as well as the ability to 
resolve infection and inflammation in animal models (96). Macrophages are very 
important in host defence as they serve as the first line of defence during infection. By 
influencing the differentiation of macrophages, IDR1018 can skew cellular responses. 
IDR1018 drives the differentiation of macrophages towards a balanced M1-M2 state 
(97). M1 macrophages are classically activated, and make inflammatory mediators as 
well as kill pathogens, while M2 macrophages are alternatively activated and have 
anti-inflammatory mediators which regulate inflammation (97). This allows anti-
inflammatory functions to occur while continuing to produce pro-inflammatory 
mediators to resolve infection quickly. IDR1018’s immunomodulatory activity has 
been demonstrated to be effective against a multidrug resistant Mycobacterium 
tuberculosis isolate, due to an increased release of chemokines as well as the 
differentiation of macrophages (98).  
 
  
IDR1018 also has antimicrobial activity against both Gram negative and positive 
bacteria. IDR1018 has stronger antimicrobial activity than Bac2a, with minimum 
inhibitory concentrations (MICs) of 19 µg/mL compared to 50 µg/mL against P. 
aeruginosa and 5 µg/mL compared to 17 µg/mL against S. aureus (8, 99). IDR1018 
has exhibited potent anti-biofilm activity against P. aeruginosa, E. coli, Acinetobacter 
baumannii, K. pneumoniae, Methicillin resistant S. aureus, Salmonella typhimurium, 
Burkholderia cenocepacia and planktonic bacteria at concentrations below their 
respective MICs (100).  
 
To date, no studies have been published looking at the efficacy of IDR1018, or related 
AMPs against neonatal pathogen isolates or in neonatal models of sepsis. The broad 
antimicrobial and immunomodulatory activities of IDR1018 suggest that it could be a 
potent adjunct therapy for current neonatal antibiotic therapies e.g. vancomycin and 
gentamicin. The rational combination of different classes of antibiotics or AMPs and 
antibiotics could provide superior empirical treatments for neonatal sepsis. 
 
1.10 Antibiotics have the ability to synergise with other antibiotics  
Antibiotics have the ability to synergise to produce an effect greater than the sum of 
two individual effects of each drug. Synergy can be determined using the fractional 
inhibitory concentration index (FICI) which calculates the interaction between two or 
more drugs by dividing the MIC of the each drug in combination, by the MIC of each 
drug alone (101). Vancomycin was shown to synergise with trimethoprim and 
nitrofurantoin to treat wild-type E.coli bacterial infections in Luria Bertani (LB) broth 
cultures - see Figure 1.4 (102). Ampicillin and gentamicin, which are more commonly 
used in developing countries against neonatal sepsis also have synergistic effects 
  
















LB: Luria Bertani broth only, VAN 25: vancomycin 25 µg/mL, TMP0.15: trimethoprim 0.15 
µg/mL, VAN25+TMP0.15: vancomycin 25 µg/mL, trimethoprim 0.15 µg/mL, 
Figure 1.4: Synergistic interaction between vancomycin and trimethoprim 






1.11 Antibiotics can synergise with AMPs to effectively treat drug resistant 
bacteria  
AMPs also have the ability to synergise with antibiotics to treat multidrug resistant 
bacteria. The antibiotic azithromycin, can synergise with antimicrobial peptide LL-37 
to treat multidrug resistance P. aeruginosa, K. pneumoniae and A. baumannii in 
standard testing conditions using RPMI-1640 and 5% LB broth as media, which was 
used due to ability to better display bactericidal effects (101). Azithromycin is not 
commonly used for serious Gram negative rod infections, but the antibacterial activity 
of azithromycin was shown to be enhanced in mammalian tissue culture such as 
RPMI1640, suggesting the antibiotic may work in vivo. In combination with LL-37 or 
antibiotic colistin, synergy with azithromycin was observed and the bacterial species 
were more effectively killed by lower doses of the combination of drugs when 
compared to the drugs alone in a time kill assay (Figure 1.5) (101).  
 
 
Figure 1.5: Multi-drug resistant bacteria P. aeruginosa, K. pneumoniae and A. 





Ciprofloxin has also been tested with LL-37 against Salmonella enterica, which 
demonstrated synergy in a checkerboard assay, which compares decreasing doses of 
antibiotics and had a significant decrease in CFU/mL when compared with the 




Figure 1.6: Activity of LL-37  in combination with Ciprofloxacin (CIP) against S. 
enterica (103). Culture time was 6 hours and 16 µM of IDR1018 and 0.025 mg/L  of  
CIP were used.  
 
The  cationic AMP, DP7, was found to be synergistic with vancomycin against 1 
isolate out of 12 tested,  of E. coli, and synergistic with 40% of S. aureus isolates tested 
(104). Synergy was determined using a microdilution checkerboard assay and the FICI 




Figure 1.7: Activity of IDR1018 and ciprofloxacin against Pseudomonas 
aeruginosa PA14 biofilms (99).  
 
IDR1018 has shown activity against bacterial isolates but has not been investigated 
for synergy between vancomycin and gentamicin, or against neonatal pathogens. In 
order to proceed with developing this AMP to use as a potential empirical therapy for 
neonatal sepsis, this information is necessary to determine whether it is a viable 
adjunct for further testing.  
 
1.12 Conclusion 
LOS in preterm infants is commonly caused by both Gram negative and positive 
organisms, such CoNS and E. coli. There are limitations in diagnosis as blood cultures 
are insensitive and slow. Due to the high risk of mortality with delayed therapy, there 
is an urgent need for effective empirical antibiotics that target both Gram positive and 
negative, such as gentamicin and vancomycin. As the causative organism has not been 
detected before empirical therapy has been commenced, the wrong antibiotics may be 
used which may contribute to the development of antimicrobial resistance. Frontline 
  
therapy must be improved to target a broader range of pathogens, including 
antimicrobial resistant strains. AMPs have broad spectrum antimicrobial properties 
and can synergise with antibiotics for improved bacterial killing. Synthetic 
antimicrobial peptides, such as IDR1018 are more potent and tolerant to physiological 
conditions than endogenous AMPs. Therefore, combinations of synthetic AMPs, such 
as IDR1018 with currently used frontline antibiotics like gentamicin and vancomycin 


















1.13 Aims of this thesis 
Overall aim: To investigate the effectiveness of IDR1018 peptide in combination with 
vancomycin or gentamicin to combat the growth and survival of common neonatal 
pathogens in human blood. 
 
Specific aims: 
1 To test difference concentrations of IDR1018 peptide in combination with 
vancomycin or gentamicin to combat the growth and survival of E. coli and S. 
epidermidis neonatal sepsis isolates under standard testing conditions. 
2 To evaluate optimal combinations of IDR1018 and antibiotics using human 
adult blood.  
3 To test whether optimal combinations of IDR1018 and antibiotics are effective 
against common antibiotic resistant neonatal bacterial species.  
 
1.14 Hypotheses 
1. That IDR1018 can combine synergistically with commonly used neonatal 
antibiotics to more rapidly inhibit and/or kill major Gram positive and negative 
neonatal pathogens under standard testing conditions. 
2. That the optimal combination of IDR1018 and antibiotic identified in Aim 1 will 
effectively inhibit and/or kill common neonatal pathogens in human adult blood. 
3. That the optimal combination of IDR1018 and antibiotics can overcome 





2. Materials and Methods  
2.1 Bacterial Stocks  
Bacterial isolates of E. coli, S. epidermidis, S. aureus, E. faecium and E. faecalis 
(Table 2.1), originally obtained from PathWest Laboratory Medicine Western 
Australia, were streaked onto Colombia sheep blood agar plates (ThermoFisher 
Scientific, VIC, Australia) from -80ºC frozen stocks, using a 10µL sterile loop and 
incubated at 37ºC for 24h. Bacterial isolates were cultured at least twice from the 
initial culture taken from frozen stock before use in any experiment.  
 
2.2 Culture media and broths 
RPMI-1640 medium with L-glutamine and sodium bicarbonate, was purchased from 
Sigma Aldrich. All media was prepared according to manufacturer’s directions and 
stored at 2-8ºC. LB broth was prepared by dissolving 25 g LB powder (Oxoid) in 1L 
of distilled and sterilised by autoclaving the solution at 121ºC for 15 minutes. 
Phosphate Buffered Saline (PBS; Oxoid) was prepared by adding three salt tablets to 
300mL distilled water and autoclaving the solution at 121C for 10 minutes. Brain 
Heart Infusion (BHI) agar was made by mixing 14.8g of BHI powder and 3g of Agar 
Bacteriological (Both from Oxoid) in 400mL of distilled water and sterilised by 
autoclaving at 121ºC for 15 minutes. Once the solution had slightly cooled, 20mL was 
poured onto each 100mm x100mm x20mm square petri dish (Sarstedt, South 
Australia) and left to set before being refrigerated at 2-8ºC. Colombia Sheep Blood 




Table 2.1. Bacterial isolates used in this study 
 
ID Strain Origin Source 
SA962 Escherichia coli Clinical Isolate Pathwest Laboratory 
SA963 Escherichia coli Clinical Isolate Pathwest Laboratory 
SA964 Escherichia coli Clinical Isolate Pathwest Laboratory 
SA966 Escherichia coli Clinical Isolate Pathwest Laboratory 
SA968 Escherichia coli Clinical Isolate Pathwest Laboratory 
SA969 Escherichia coli Clinical Isolate Pathwest Laboratory 
SA970 Escherichia coli Clinical Isolate Pathwest Laboratory 
SA971 Escherichia coli Clinical Isolate Pathwest Laboratory 
SA972 Escherichia coli Clinical Isolate Pathwest Laboratory 
SA973 Escherichia coli Clinical Isolate Pathwest Laboratory 
ATCC25922 Escherichia coli Clinical Isolate ATCC 
SA910 Staphylococcus epidermidis Clinical Isolate Pathwest Laboratory 
SA912 Staphylococcus epidermidis Clinical Isolate Pathwest Laboratory 
SA913 Staphylococcus epidermidis Clinical Isolate Pathwest Laboratory 
SA914 Staphylococcus epidermidis Clinical Isolate Pathwest Laboratory 
SA915 Staphylococcus epidermidis Clinical Isolate Pathwest Laboratory 
SA916 Staphylococcus epidermidis Clinical Isolate Pathwest Laboratory 
  
SA917 Staphylococcus epidermidis Clinical Isolate Pathwest Laboratory 
SA918 Staphylococcus epidermidis Clinical Isolate Pathwest Laboratory 
SA919 Staphylococcus epidermidis Clinical Isolate Pathwest Laboratory 
ATCC14990 Staphylococcus epidermidis Clinical Isolate ATCC 
VISA Staphylococcus aureus Clinical Isolate 
Dr Sam Abraham, 
Murdoch University 
ATCC29213 Staphylococcus aureus Clinical Isolate ATCC 
VAN B VRE Enterococcus faecium Clinical Isolate 
Dr Sam Abraham, 
Murdoch University 
ATCC29212 Enterococcus faecalis Clinical Isolate ATCC 
 
 
2.3 Antibiotics and Antimicrobial Peptides  
2.3.1 Source and reconstitution information for antibiotics and IDR1018 
Gentamicin was sourced from Sigma Aldrich (NSW, Australia; batch number 
108M4841V) and vancomycin was sourced from King Edward Memorial Hospital, 
Western Australia (batch numbers: Hospira 7076913AA and Alphafarm 187139). 
Both antibiotics were stored at 2- 8ºC until use and reconstituted using sterile water. 
IDR1018 (VRLIVAVRIWRR- NH2) was synthesised by CPC Scientific (Sunnyvale, 
CA) using solid phase Fmoc chemistry and the peptide mass was confirmed by mass 
spectrometry. IDR-1018 was kindly supplied by Prof Bob Hancock (University of 
British Colombia). IDR1018 was stored at -80ºC until it was thawed for use. 
 
  
2.3.2 Reconstitution and dilution of antibiotics and IDR1018 
Antibiotic powders were weighed to 2 decimal places and reconstituted using sterile 
water. The following formula, that is provided by the Clinical and Laboratory 
Standards Institute (CLSI) guidelines (105), was used to determine the volume of 
water required to produce a stock concentration of antibiotics at the desired 
concentration: 
Volume of water (ml) = (Weight of antibiotic (mg) x Potency of antibiotic (ug/mg)) / 
Concentration of antibiotic (ug/mL)  
The potency was obtained from the Lot-specific antibiotic certificate of analysis for 
each antibiotic, available from the Sigma -Aldrich website. All antibiotics were diluted 
1/20 into RPMI + 5% (v/v) Luria Bertani broth (LB Oxoid). 
IDR1018 stock solution (1.5 mg/mL) was diluted using RPMI-1640 + 5% (v/v) LB to 
the required concentrations on the day of use.  
 
2.4 Healthy adult blood donors 
Blood samples were sourced from recruited healthy adult donors aged between 18-60 
years of age from the Murdoch University Campus and collected under approval of 
the Murdoch University Human Research Ethics Committee (Project Number 
2016/031). All participants were assigned blinded study numbers so that donors were 
deidentified for all analyses.  
 
  
2.5 Collection and processing of blood samples 
Peripheral blood samples (5 mL) were taken from 8 donors by a trained phlebotomist 
using venepuncture into Vacuette Serum Clot activator 6 mL tubes (Greiner Bio-One, 
North Carolina). Collected blood was left to sit for 15-30 minutes at room temperature 
to allow the blood to clot, and then processed into serum by centrifuging at 1000 x g 
for 15 minutes at room temperature. A single aliquot (200 µL) of serum from each 
donor was removed, stored in a 3mL polypropylene tube, and frozen at -20ºC for 
future experimental use. The remaining serum (~ 2.5mL) from each donor was 
removed and combined into a single serum ‘pool’ in a 20 mL polypropylene tube. The 
original blood tubes were centrifuged again at 1000 x g for 15 minutes at room 
temperature and any additional serum was added to the pooled polypropylene tube. 
Pooled serum was immediately used for time-to-kill assays (Section 2.10) and the 




2.6 Determining Minimum Inhibitory Concentrations (MICs) of 
Antibiotics and IDR1018 
Minimum Inhibitory Concentration (MIC) experiments were conducted using Clinical 
Laboratory Standards Institute (CLSI) protocol M07-A10 (105) to measure the in-
vitro activity of antibiotics against each bacterial isolate. Ninety µL of RPMI-1640 + 
5% LB was added to each well of a sterile, U-bottom 96 well plate (Thermofisher) 
with the exception of row 1. Ninety µL of a range of concentrations of vancomycin 
(100 µg/mL to 300 µg/mL), gentamicin (20 µg/mL to 100 µg/mL) or IDR1018 
(15 µg/mL), were added the row 1 of the plate. The antibiotics and IDR018 were 
serially diluted downwards starting with row 1, in 90µL aliquots, with mixing in 
between, discarding 90µL from the final row of wells. A fixed inoculum of each 
bacterial isolate was made by suspending 2-3 colonies from overnight SBA cultures 
in ~5mL PBS to a turbidity equivalent to a 0.5 McFarland standard (approximately 1-
2x108 CFU/mL). The inoculum was then diluted 1/20 with RPMI-1640 + 5%(v/v) LB 
and 10 µL added to each well of same U-bottom 96 well plate containing antibiotics 
and IDR1018, giving a final volume of 100 µL in each well. Each isolate/antibiotic 
concentration was performed in triplicate on the plate, and plates were repeated 3 
times. MICs were performed for all isolates in Table 2.1. MIC plates were incubated 
for 18-24 hours at 37ºC under aerobic conditions. Plates were read visually using the 
Sensititre Vizion instrument (Thermofisher) which captures a fixed image of the 96 






2.7 Determining Minimum Bactericidal Concentrations (MBCs) 
After visually reading the MIC plates, 10 µL from each well of the 96 well plate was 
removed and spotted directly onto BHI agar to determine the minimum bactericidal 
concentration (MBC). These plates were left to dry and then incubated at 37ºC for 18-
24 hours to determine colony forming units (CFU).  
 
2.8 MALDI-TOF  
MALDI-TOF was performed to confirm the identity of the S. epidermidis isolates in 
Table 2.1. A small sample of a single colony of bacteria, grown overnight in SBA was 
added to the MSP 96 polished steel target plate (Bruker, VIC, Australia) and 1 µL of 
matrix was added onto each sample before being read by the Microflex MALDI-TOF 
mass spectrophotometer (Bruker).  
 
2.9 Checkerboard assay to test synergy of antibiotics and IDR1018  
Checkerboard assays were run using an optimised version of CLSI MIC protocol M07-
A10 (2012) to test for synergy between vancomycin or gentamicin and IDR1018. 
Ninety µL of RPMI-1640 + 5% LB was added to each well of the 96 well 
polypropylene plate. Antibiotics, which were added to column 12 of the plate, were 
prepared at 4 times the final concentration desired, as the plate must be serially diluted 
initially across the X-axis and then down the Y-axis as seen in Figure 2.1. IDR1018 
which was added to row 1 was prepared at two times the final concentration desired. 
Peptide was not diluted into the last row (row H) of the 96 well plate and antibiotics 
were not diluted into column 1 of the plate.  
 
  
Figure 2.1. Diagram showing the dilution series performed on 96 well plate 
dilution series for the antibiotic/IDR1018 checkerboard assay. Arrows represent 
direction that drugs were serially diluted. Black arrow represents antibiotic dilution, 
which is performed first. Blue arrow represents IDR1018 dilution, which is performed 
second.  
The inoculum for each plate was made by suspending the bacterial isolate to be tested 
in PBS to a turbidity equivalent to a 0.5 McFarland standard (approximately 1-2x108 
CFU/mL) after growing the bacteria on SBA for 18-24 hours. The inoculum was then 
diluted 1/20 with RPMI-1640 + 5% LB and 10 µL was added to each well. The plates 
were incubated at 37ºC for 18-24 hours before results were read visually using 
Sensititre Vizion (Thermofisher). All plates were run in duplicate and VISA, 
vancomycin sensitive S. aureus and 5 strains of E. coli (ATCC 29213, SA964, SA966, 
SA969 and SA971) were tested. 
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2.10 Antibiotic/IDR1018 Time-Kill assays using pooled human serum 
Time to kill assays were performed using an optimised version of CLSI Time-Kill 
protocol M26-A (106) to measure the activity of the synergistic combination of 
IDR1018 and vancomycin determined in Section 2.5 against E. coli and S. aureus in 
diluted (20% using  RPMI-1640 + 5% LB) pooled human serum.   
1.7ml of RPMI-1640 + 5% LB +20% serum was added to sterile 2ml borosilicate glass 
test tubes (table 2.5), except for the control tubes, to which 1.7ml RPMI-1640 + 5% 
LB was added. Working stocks of antibiotics and IDR1018 were prepared at 40x the 
final desired concentration by diluting in RPMI-1640 + 5% LB + 20% serum. 50 µL 
of each antibiotic and/or IDR1018 working stock was added to the 1.7 mL of diluted 
pooled serum tubes, along with 50 µL of RPMI-1640 + 5% LB if required, to give a 
final volume of 1.8 mL in each tube. 
A 0.5 McFarland standard of either S. aureus or E. coli from SBA plates was prepared 
and diluted 1/20 in PBS. 200 µL of the diluted bacteria inoculum was added to each 
tube, giving a final volume of 2 mL in all tubes. Tubes were mixed and placed into the 
incubator at 37ºC, shaking at 100rpm. At each of the time points ( 0, 2, 4 and 24 hours) 
10 µL from each tube was added to a top well of a 96 well plate containing 90 µL of 
PBS per well. 10 µL was serially diluted down, starting with row 1 and mixed in 
between. 10 µL from each of the wells was spotted onto BHI agar plates and incubated 
at 37ºC for 24 hours. Results were read by counting the individual colonies that grew 
after 24 hours.  
 
  
The above experiment was repeated for vancomycin, and vancomycin combined with 
IDR018, for E. coli only using diluted pooled human serum and diluted, heat-treated 
pooled human serum, which was heated for 70ºC for 10 minutes before use.  
 
2.11 Fluorescent Microscopy  
Slides were set up for fluorescent microscopy to determine the mode of action of the 
IDR1018 peptide and vancomycin. E. coli ATCC 25922 was grown overnight in 10 
mL RPMI + 5% LB in a 50 mL glass test tube at 37ºC. Density was measured at OD 
600nm and adjusted to 0.05 using RPMI 1640 + 5% LB to prepare as starting culture. 
Mid-log cultures were prepared by incubating the starting culture for 50 minutes at 
37ºC (107). Mid-log culture was centrifuged for 10 minutes at 300 g and resuspended 
in 1mL RPMI-1640 + 5%. 14.2µL of concentrated mid-log culture was aliquoted into 
1.5mL Eppendorf tubes and covered with foil. PBS or Invitrogen BODIPY FL 
Conjugate fluorescent vancomycin (2.34 µg/mL) (Thermo Fisher), with or without 
IDR1018 (7.5 µg/mL), were added to the tubes. All tubes were incubated at 30ºC with 
shaking for 30 minutes.  
100µL of sterile water was added to 1mg DAPI and diluted 1:5000 in PBS. The diluted 
DAPI (2µg/mL) was added to each tube and incubated at room temperature for 10 
minutes. 15µl from each tube was spotted onto a glass microscope slide treated with 
poly-L-lysine and left to dry. Slides were treated with 4% (w/v) paraformaldehyde for 
10 minutes and washed with sterile water. Coverslips were mounted using a no-fade 
mounting media and sealed with nail varnish.  
 
  
2.12 Statistical analysis of time-to-kill curves 
The data collected from the time-to-kill using human serum were analysed using 
statistical data analysis software GraphPad Prismâ v8 (La Jolla, California USA, 
www.graphpad.com). All data were tested for statistical significance using a 
Friedman’s (non-parametric) two way analysis of variance (ANOVA) and a Tukey’s 
multiple comparison to test statistical significant difference between the means of 
















3.1 Minimum Inhibitory Concentrations of Vancomycin and Gentamicin 
against S. epidermidis and E. coli 
In order to determine the working antibiotic concentrations for the 
IDR1018/antibiotic synergy experiments (Section 3.6),  the MICs of vancomycin 
and gentamicin using 11 strains each of E. coli and S. epidermidis using a modified 
CLSI broth microdilution method (Section 2.6) were determined. MICs for the E. 
coli isolates varied between 0.31 µg/mL to >300 µg/mL depending on the antibiotic 
tested (Figure 3.1A). Vancomycin had an MIC of >300 µg/mL for 5/11 of the E. 
coli isolates tested, whereas another 5/11 isolates had MICs between 150 -300 
µg/mL (Table 3.1). A single isolate, SA966 had an MIC of 75 µg/mL. In contrast, 
all 11 E. coli isolates had MICs for gentamicin ≤ 1.25 µg/mL. 
 
None of the 11 S. epidermidis isolates grew in the 96 well culture plate, including 
the growth control wells without antibiotics, so MICs could not be determined 
(Figure 3.1B). The MIC determinations for S. epidermidis isolates were repeated to 
ensure that the lack of growth was not due to human error, with no growth occurring 
in any of the wells during the repeated experiment. Further attempts to optimise 









= visible high bacterial growth  = visible intermediate bacterial growth 
= no visible bacterial growth 
 
Figure 3.1: Determination of vancomycin and gentamicin MICs using the 
CLSI broth microdilution method. Data shown are representative images from 3 
strains each of: A) Escherichia coli and B) Staphylococcus epidermidis. Minimum 
inhibitory concentrations were determined from the first wells that had no visible 
bacterial cell pellet.  
  
Table 3.1: MICs of vancomycin and gentamicin against E. coli isolates using the 
CLSI broth microdilution method. Concentrations of 0.16 to 20 µg/mL for 
gentamicin and 2.3 µg/mL to 300 µg/mL for vancomycin were tested. Plates were 
incubated for 24 hours at 37ºC. Data shown are mean MICs from 3 separate 







SA962 300 0.94 
SA963 >300 1.25 
SA964 >300 1.25 
SA966 75 0.63 
SA968 >300 0.31 
SA969 225 1.25 
SA970 150 1.25 
SA971 >300 0.63 
SA972 150 0.63 
SA973 150 0.47 






3.2 Minimum bactericidal concentrations (MBC) of vancomycin and 
gentamicin against E. coli isolates. 
After examining the MICs, the MBCs were measured from the same 96 well plates 
to determine the minimum concentration of drug required to kill the bacteria (see 
Section 2.8). For gentamicin, the MBC was 1.5 to 6.5 times higher than the 
corresponding MIC for each E. coli isolate. For vancomycin, the MBC was 2-4 
times higher than the corresponding MIC for 5 isolates and equivalent to the MIC 


















Table 3.2: MBCs of vancomycin and gentamicin against E. coli isolates using 
the CLSI broth microdilution method. Gentamicin doses ranged from 0.16 
µg/mL to 20 µg/mL, and vancomycin doses range from 2.3 µg/mL to 300 µg/mL. 
Plates were incubated for 24 hours at 37ºC. Data shown are the mean MBCs from 







SA962 300 3.75 
SA963 >300 5 
SA964 >300 5 
SA966 >300 2.5 
SA968 >300 2 
SA969 >300 3.75 
SA970 300 1.88 
SA971 300 1.25 
SA972 >300 1.56 
SA973 >300 0.94 




3.3 Optimisation of S. epidermidis growth 
A number of experiments were performed in an attempt to grow S. epidermidis in 
the RPMI-1640 +5% LB media used in the CLSI microdilution protocol.  
Firstly, a MALDI-TOF mass spectrometer was used to confirm that all bacterial 
isolate stocks contained only S. epidermidis, which was the case (data not shown). 
Next, to determine if volume of culture media in the microplate was too low for 
adequate growth, the ATCC 25922 S. epidermidis isolate was cultured at the same 
starting inoculum (0.5 McFarland standard) in a larger volume (1 mL) of RPMI-
1640 + 5% (v/v) LB in glass test tubes. Growth was observed under these conditions 









Figure 3.2: Growth media determination for S. epidermidis. Bacteria were 
grown in glass test tubes and incubated in aerobic conditions for 24 hours at 37ºC 
before growth in tubes was visualised. Cultures were resuspended and pipetted into 
a 96 well plate (shown) for absorbance measurements.  
 
The culture of ATCC 25922 was also trialled in 2 mL of 10 different media 
combinations in glass test tubes (Figure 3.2) and assessed for visible growth and 
absorbance at 600nm (Table 3.3). There was visible growth in all media, except 
those containing glucose; 100% DMEM (high glucose) and RPMI-1640 + 2% (v/v) 
glucose. The highest density of bacterial growth (A600nm of 0.47) was recorded in 
RPMI-1640 +20% LB (v/v), followed by RPMI-1640 +10% (v/v) bovine serum 






Table 3.3: Growth of S. epidermidis in 2 mL cultures with different media. 
S. epidermidis ATCC 25922 was grown in 10 different media combinations in tubes 








100% Luria Bertani (LB) + 0.23 
100% RPMI-1640 + 0.25 
95% RPMI-1640 + 5% LB + 0.37 
80% RPMI-1640 + 20% LB + 0.47 
50% RPMI-1640 + 50% LB + 0.40 
90% RPMI-1640 + 10% Serum + 0.45 
100% DMEM (high glucose) - 0.01 
90% DMEM + 10% serum + 0.42 
98% RPMI-1640 + 2% glucose - 0.01 




From these culture experiments, it was concluded that S. epidermidis could grow in 
larger volumes (1-2 mL) of RPMI-1640 + 5% (v/v) LB. An experiment was 
performed to confirm that the 0.5 McFarland standard could not grow in in the same 
medium at a volume of 100 µL (Figure 3.3). Although the 0.5 McFarland standard 
of S. epidermidis had visible growth in LB broth, and the overnight culture of 
  
bacteria in RPMI-1640 also had visible growth, there was no visible growth in the 
100 µL culture of the 0.5 McFarland standard in RPMI-1640 + 5% LB.  
 
 
Figure 3.3: Growth of S. epidermidis ATCC 25922 in small volumes of RPMI-
1640. Experiment was performed in duplicate and plates were incubated under aerobic 
conditions at 37ºC for 24 hours. 
 
Due the lack of growth of S. epidermidis under standard CLSI microdilution 
conditions, and to time constraints of the project, a decision was made to switch to 
Staphylococcus aureus as the staphylococcal isolate investigated in this project. 
Both a vancomycin intermediate and sensitive strain of S. aureus were investigated. 
Additionally, two other Gram positive organisms were investigated, the 
Enterococcal species, E. faecalis and vancomycin resistant E. faecium were 
included to introduce vancomycin sensitive and resistant strains. 
  
 
3.4 MBC and MICs of S. aureus, E. faecium and E. faecalis 
Unlike S. epidermidis, these replacement Gram positive isolates grew in the CLSI 
microdilution conditions (Fig 3.4). To determine the minimum concentrations needed 
of each isolate, I determined the MICs and MBCs for vancomycin and gentamicin 
against vancomycin sensitive S. aureus, vancomycin intermediate S. aureus (VISA), 
vancomycin sensitive E. faecalis and vancomycin resistant E. faecium (Table 3.4). 
Vancomycin had a MIC of 12.25 µg/mL and MBC of 25 µg/mL against vancomycin 
sensitive E. faecalis, whereas gentamicin had an MIC and MBC of <0.77 µg/mL 
(Table 3.4). The vancomycin resistant Enterococci, E. faecium, had a vancomycin 
MIC and MBC of 300 µg/mL, whereas gentamicin had an MIC and MBC of >100 
µg/mL (the highest concentration tested). The vancomycin sensitive S. aureus, ATCC 
29213, had a vancomycin MIC of 3.06 µg/mL, with an MBC 1.5 times greater, while 
gentamicin had a MIC of <0.77 µg/mL (lowest concentration tested) and MBC of 1.53 
µg/mL. The vancomycin intermediate S. aureus, had a vancomycin MIC and MBC of 
<2.34 µg/mL (the lowest concentration tested) and a gentamicin MIC of <0.77 µg/mL 




Figure 3.4: Growth and inhibition of S. aureus and E. faecium using the CLSI 
broth microdilution method. Data shown are representative images from A) S. 
aureus ATCC29213 and B) E. faecium VRE. Minimum inhibitory concentrations 
were determined from the first wells that had no visible bacterial cell pellet. *As E. 
faecium VRE is resistant against vancomycin, a higher initial concentration of 300 
µg/mL vancomycin was used, and serially diluted to 2.34 µg/mL at the lowest 
concentration. The initial and final concentration of gentamicin remained the same. 











3.5 Minimum inhibitory concentrations of IDR1018 
MICs for IDR1018 were determined from the checkerboard assay wells which did not 
contain either gentamicin or vancomycin (Figure 3.5 & Table 3.5). E. coli ATCC 
29213 required the highest concentration of IDR1018 with inhibition at 15 µg/mL, 
and E. faecium VRE required the lowest concentration of IDR1018 with inhibition at 
1.88 µg/mL.  
 
Table 3.4: MIC and MBC results for two isolates of S. aureus and one of both E. 
faecium and E. faecalis treated with vancomycin or gentamicin using the CLSI 
broth microdilution method. Gentamicin concentrations range from 0.77 µg/mL to 
100 µg/mL and vancomycin doses range from 2.3 µg/mL to 300 µg/mL. Plates were 
incubated for 24 hours at 37ºC. Data shown are the mean MICs and MBCs from 3 
separate experiments for each isolate performed in duplicate on each day. 
 
Isolate 
Vancomycin (µg/mL) Gentamicin (µg/mL) 
MIC MBC MIC MBC 
S. aureus  
ATCC 29213 
3.06 4.6 <0.77 1.53 
S. aureus VISA <2.34 <2.34 <0.77 4.69 
E. faecalis 
ATCC 29212 
12.25 25 <0.77 <0.77 




Table 3.5: MIC results for E. coli ATCC 25922, S. aureus ATCC 29213 and E. 
faecium VRE treated with IDR1018. MICs were based on the IDR1018 only wells 
from checkerboards of each isolate. Data shown are mean of two separate experiments 
for each isolate performed in duplicate on each day.  
Isolate IDR1018 (µg/mL) 
E. coli ATCC 25922 15 
S. aureus ATCC 29213 3.75 
E. faecium VRE 1.88 
 
 
3.6 Antibiotic/IDR1018 checkerboard assays  
To determine whether synergy occurred between IDR1018 and vancomycin or 
gentamicin, checkerboard assays (see Section 2.10) were performed against 5 isolates 
of E. coli (ATCC 29213, SA964, SA966, SA969 and SA971), and a single isolate each 
of E. faecium VRE, E. faecalis, VISA and S. aureus. Drug activity was determined 
using the fractional inhibitory concentration index (FICI), which classifies synergy at 
≤ 0.5 and additive effects at >0.5 to ≤ 1. Antagonistic effects are classified at >1. 
 
For E. coli ATCC29213 (Figure 3.4), synergy was determined at 2 different 
concentration combinations; with IDR1018 at a concentration of 3.75 µg/mL and 
vancomycin at 37.5 µg/mL, and with IDR1018 at a concentration of 7.5 µg/mL and 
vancomycin at 2.4 µg/mL (Table 3.6). FICI was calculated to be 0.5 for both 
concentrations which were therefore synergistic. Multiple additive combinations 
(FICI of ≥0.53) were also observed for IDR1018 at a concentration of 7.5 µg/mL and 
  
vancomycin concentrations of 4.7 µg/mL or greater (Figure 3.5). There was no 
synergy determined between IDR1018 and gentamicin against E. coli ATCC29213 
(figure 3.5), and at most concentration combinations there was also no additive effect. 
The only exception was the combination of 7.5 µg/mL of IDR1018 with 0.4 µg/mL of 


















= Synergistic combination 
 
 
Figure 3.5: Checkerboard assay combining increasing concentrations of A) 
IDR1018 and vancomycin against E. coli ATCC29213 and B) IDR1018 and 
gentamicin against E. coli ATCC 29213. Data shows a representative plate (isolate 
ATCC 29213) from 1 of 5 of E. coli isolates tested, with three experiments performed 
for each isolate. Starting inoculum was 0.5 McFarland standard, and plates were 
incubated in aerobic conditions at 37ºC for 24 hours. 
  
There was no synergy or additive effect for any combination of IDR1018 and 
vancomycin against S. aureus ATCC 29213 (Figure 3.6). However, there was some 
antagonistic effect at certain concentrations; 3.75 µg/mL IDR1018 and 0.1 µg/mL 
vancomycin, and 3.75 µg/mL IDR1018 and 0.4 µg/mL of vancomycin with a FICI of 
2.1 and 2.5 respectively. No synergistic, antagonistic or additive effects were noted 
for any combination of IDR1018 and gentamicin against S. aureus ATCC 29213 
(Figure 3.7). Each drug worked as effectively as a monotherapy as they did in 
combination.  
 
Although E. faecium VRE had no synergistic combinations at any concentration of 
IDR1018 and vancomycin, there was an additive effect at 3.75 µg/mL IDR1018 and 
150 µg/mL of vancomycin with an FICI of 1 (Figure 3.7). There was also antagonistic 
effects (FICI of 2) at concentrations of IDR1018 of 3.75 µg/mL with vancomycin 














Figure 3.6: Checkerboard assay combining A) increasing doses of IDR1018 and 
increasing doses of vancomycin against S. aureus ATCC 29213 and B) increasing 
doses of IDR1018 and increasing doses of gentamicin against S. aureus ATCC 29213. 
Data shown are representative images with three replicates. Starting inoculum was 0.5 






Figure 3.7: Checkerboard assay combining A) increasing doses of IDR1018 and 
increasing doses of vancomycin against E. faecalis VRE and B) increasing doses of 
IDR1018 and increasing doses of gentamicin against E. faecalis Data shown are 
representative images with three replicates. Starting inoculum was 0.5 McFarland 




Table 3.6: Synergistic concentrations of IDR1018 and vancomycin determined 
from checkerboard assay. Synergy was determined using the FICI and were ≤ 0.5. 
Checkerboards were replicated three times and incubated in aerobic conditions at 37ºC 






E. coli ATCC 25922 7.5 2.4 
E. coli ATCC 25922 3.75 37.5 
E. coli SA971 7.5 18.8 
E. coli SA971 3.75 37.5 
E. coli SA696 3.75 75 
 
 
3.6 Time-to-kill assays using optimal synergistic combination of IDR1018 
and vancomycin 
To determine if the synergistic combination of IDR1018 and vancomycin, determined 
in the checkerboard assays, could work effectively against E. coli ATCC 25922 and 
S. aureus ATCC 29213 under more physiological conditions, the combination was 
tested using 20% pooled serum diluted with RPMI-1640 and 5% LB (see Section 
2.10). Given the limited amount of serum available, only one of the effective 
combinations of concentrations - 7.5 µg/mL IDR1018 and 2.4 ug/mL vancomycin - 
was used. The other combination had a vancomycin concentration of 37.5 µg/mL, 
  
which sits above the clinical recommendation for vancomycin trough levels to remain 
below 25 µg/mL to avoid toxicity (57).  
 
Each isolate was cultured either in the diluted pooled serum alone, or in the presence 
of vancomycin (300 µg/mL), IDR1018 (15 µg/mL), IDR1018 and vancomycin 
combined (7.5 µg/mL and 2.4 µg/mL, respectively), or with vancomycin and 
gentamicin combined (0.8 µg/mL and 2.34 v, respectively) for S. aureus and (300 
µg/mL and 0.8 µg/mL, respectively) for E. coli. Aliquots were taken at time points 
over 24 hours and remaining CFU determined by culture on BHI agar (see Section 
2.10).  
 
3.6.1 Time-to-kill assay against E. coli  
The CFU/mL of E. coli increased ~8-fold in the diluted serum alone over 24 hours 
from a starting inoculum of 3.8x106 CFU/mL (Figure 3.11A). When vancomycin 
alone was added to the serum, E. coli decreased ~87-fold over 24 hours from 2.6 x106 
CFU/mL to 1.2x105 CFU/mL. In the presence of IDR1018 alone, E. coli decreased 
2.5-fold over 24 hours from 2.5x106 to 1x106 CFU/mL. The CFU/mL of E.coli in the 
presence of the synergistic combination of IDR1018 and vancomycin, decreased 94-
fold over 24 hours from 1.6x106 CFU/mL to 1.7x104 CFU/mL. As shown in the time-
to-kill curve, the vancomycin and gentamicin combination was the only combination 





3.6.2 Time-to-kill assay against S. aureus 
The CFU/mL of S. aureus increased ~48 -fold in the diluted serum alone over 24 
hours, from a starting inoculum of 1.45x106 CFU/mL (Figure 3.11B). When 
vancomycin alone was added to the serum, S. aureus was decreased to below the limit 
of detection (300 CFU/mL). In the presence of IDR1018 alone, the CFU/mL increased 
by ~5-fold, from 1.9x106 to 9.4x106 million in 24 hours. The density of S. aureus 
initially dropped 60-fold after 4 hours with the combination of vancomycin and 
gentamicin but then increased to be 17- fold higher than the starting inoculum by 24 
hours. S. aureus was decreased to below the limit of detection (300 CFU/mL) when 



























Figure 3.8: Representative time-to-kill using a synergistic combination of 
IDR1018 and vancomycin against E. coli. Concentrations of IDR1018 and 
vancomycin were 7.5 µg/mL and 2.34 µg/mL respectively. Time-to-kills were 






Figure 3.9: Time-to-kill curves against E. coli and S. aureus using pooled human 
serum. A) E. coli ATCC25922 B) S. aureus ATCC29213. Tubes were incubated in 
aerobic conditions at 37ºC before samples were removed at each time point. Samples 
were then spotted onto BHI agar and incubated for 24hr at 37ºC in aerobic conditions. 
Data shown are mean CFU/mL ± standard deviation, n = 6 experiments. Dashed line 
shows assay lower limit of detection at 300 CFU/mL. aP< 0.05 comparing CFU/mL 
of vancomycin against no drugs, bP< 0.05 comparing CFU/mL of IDR1018 vs no 
drugs, cP< 0.5 comparing CFU/mL of IDR1018/Vancomycin vs no drugs, dP< 0.5 
comparing CFU/mL of vancomycin/gentamicin vs no drugs, eP< 0.05 comparing 
CFU/mL of vancomycin and gentamicin vs vancomycin. All comparisons were made 
using Friedman’s two-way ANOVA with Tukey’s test. 

















































3.7 Time-to-kill assay against E. coli using heat treated serum 
Due to the lack of synergistic activity shown by the combination of IDR1018 and 
vancomycin against E. coli in diluted human serum, the experiment was repeated using 
heat-treated serum (see Section 2.11) to test for possible heat-labile inhibitors (Figure 
3.14). The density of E. coli increased ~70,000-fold in the diluted heat-treated serum 
alone over 24 hours from 2.9x106 CFU/mL to 2.01x1011 CFU/mL (Figure 3.13). The 
synergistic combination of IDR1018 and vancomycin reduced the bacterial density 
below the limit of detection after 4 hours, and the density only increased to 500 











Figure 3.10: Time-to-kill curves against E. coli ATCC 25922 using pooled human 
serum heated to 70ºC. Tubes were incubated in aerobic conditions at 37ºC before 
samples were removed at each time point. Samples were then spotted onto BHI agar 
and incubated for 24hr at 37ºC in aerobic conditions. Data shown are mean CFU/mL 
±standard deviation, n=6 experiments. aP<0.05 comparing CFU/mL of 
IDR1018/vancomycin against no drugs. aaP <0.01 comparing CFU/mL of IDR1018/ 
vancomycin against no drugs. All comparisons were made using a one-way ANOVA 





3.8 Fluorescence microscopy 
Fluorescence microscopy was attempted twice in order to determine the mode of 
action of IDR1018 and vancomycin. Unfortunately, due to problems with attachment 
of the bacteria to the microscope slide, and time constraints we were unable to 
visualise the bacteria.  
 







































Figure 3.11: Representative time-to-kill using heat treated serum and synergistic 
combination of IDR1018 and vancomycin against E. coli. Concentrations of 
IDR1018 and vancomycin were 7.5 µg/mL and 2.34 µg/mL respectively. Time-to-




Empirical antibiotic therapy is necessary for the treatment of neonatal sepsis as blood 
cultures can take up to 48 hours to determine causative organisms (32). Empirical therapy 
is not always effective - the pathogen may be resistant to the chosen antibiotic therapy, 
or antibiotics chosen are the wrong class of drugs for the causative pathogen/s (19). New 
treatments are needed to improve empirical therapy against a broader range of 
microorganisms, including resistant strains. Antimicrobial peptides, such as LL-37 have 
shown promise as a novel broad spectrum antibacterial therapies with the ability to 
synergise with commonly used antibiotics (103). Newer, synthetic AMP derivatives, such 
as IDR1018 are potentially more potent and have immune modulating activity (100). 
However, the ability of IDR1018 to work against common neonatal pathogens and to 
synergise with antibiotics routinely used in neonates, such as vancomycin and 
gentamicin, has not yet been determined. 
 
In this study, I determined the MICs of IDR1018, vancomycin and gentamicin against  
isolates of E. coli, vancomycin sensitive S. aureus and VISA, vancomycin resistant E. 
faecium and vancomycin sensitive E. faecalis, and attempted to test S. epidermidis but 
was unable to culture the bacteria under standard CLSI conditions. Checkerboard assays 
were then performed using these MICs as a dose guide to determine whether any synergy 
occurred with combinations IDR1018 and vancomycin or gentamicin. To determine 
whether the synergistic drug combination could potentially work in human serum, a time-
to-kill assay was set up to examine the rapidity of the drug, as well as the effectiveness 
of inhibition against both S. aureus and E. coli.  
 
It was hypothesised that IDR1018 would be able to combine synergistically with 
vancomycin and gentamicin against Gram negative and positive neonatal pathogens. It 
  
was also hypothesised that this synergistic combination would be effective against the 
pathogens in a human blood model. 
 
The main findings from my studies were as follows: 
1) IDR1018 monotherapy was able to inhibit the growth of E. coli, E. faecium, E. 
faecalis and S. aureus using standard CLSI conditions. 
2) Vancomycin had limited activity against E. coli as a monotherapy, but showed 
additive and synergistic activity when combined with IDR1018 under standard 
conditions. 
3) The synergistic combination of vancomycin and IDR1018 had reduced activity in 
the presence of pooled human serum, but synergy was restored by heat treatment 
of the serum. 
 
4.1 Activity of IDR1018 against neonatal pathogens 
IDR1018 showed antimicrobial activity against E. coli, E. faecium, E. faecalis and S. 
aureus with MICs ranging from 1.88 to 15 µg/mL. In a study by de la Fuente-Núñez, et 
al., IDR1018 was tested against biofilm formation of a range of Gram positive and 
negative pathogens, including S. aureus and E. coli (100). It was found that at 20 µg/mL 
of IDR1018, biofilm formation was prevented and mature biofilms were eradicated. A 
similar microdilution method, although not the CLSI methods used in our project, was 
followed. More similarly to our research, MICs for IDR1018 were performed against S. 
aureus in Mueller-Hinton broth using CLSI microdilution methods, and was found to 
inhibit the bacteria at 20 µg/mL (108). These findings are consistent with our research, as  
in our study, S. aureus was inhibited by 15 µg/mL of IDR1018. Our MICs were 
performed in RPMI-1640, which may improve the activity of IDR018 as it has been 
  
suggested that eukaryotic cell media like RPMI-1640 are more effective in determining 
bactericidal activity in conditions similar to in-vivo (101). 
 
Our study has shown that IDR1018 is a broad spectrum AMP, that has the ability to kill 
Gram positive and negative bacteria including two major neonatal pathogens, E. coli and 
S. aureus. This shows promise for use as an empirical therapy for neonatal sepsis, as both 
types of bacteria can be targeted effectively, without requiring the identification of the 
causative organisms. 
 
A limitation of this part of the study was the inability to test the MIC of IDR1018 against 
S. epidermidis. S. epidermidis is the predominant Gram positive neonatal sepsis pathogen 
in LOS, causing 55% of all infections (23). However, it should be noted that S. aureus is 
still major neonatal pathogen, from the same Staphylococcus genus, and is associated 
with 9% of neonatal sepsis infections (23). If time had allowed, it may have been prudent 
to attempt to grow more isolates of S. epidermidis, although 11 isolates were attempted, 
suggesting a species-level difference in culture. As RPMI-1640 + 5% LB seemed to 
inhibit the growth of S. epidermidis, it is possible using a phenol free  RPMI-1640 + 5% 
LB may have allowed the bacteria to grow (109). Future studies could also include other 
CoNS species such as Staphylococcus saprophyticus or Staphylococcus haemolyticus. 
 
4.2 IDR1018 synergises with vancomycin against E. coli  
IDR1018 and vancomycin synergised against E. coli under standard testing conditions 
using RPMI640 media, and there was additive effects with IDR1018 and vancomycin 
against VRE. The MIC of vancomycin for majority of E. coli isolates was >300 µg/mL 
and the MBC was >300 µg/mL for all E. coli isolates. In contrast, when vancomycin was 
  
combined with IDR1018 at 7.5 µg/mL, a dose of only 2.4 µg/mL of vancomycin was 
needed to kill E. coli.  
 
Although to date, no published studies have investigated synergy between IDR1018 and 
vancomycin. IDR1018 has been shown to synergise with antibiotics such as ceftazidime 
and tobramycin against a range of Gram positive and negative bacteria including S. 
aureus and E. coli, respectively with a concentration of 10 µg/mL IDR1018 for E. coli 
and 2.5 µg/mL for S. aureus. There have also been studies conducted looking at synergy 
between vancomycin and other antibiotics, such as beta-lactams. Vancomycin has the 
ability to synergise with beta-lactam, imipenem against multiple isolates of methicillin-
resistant S. aureus (MRSA) and methicillin-sensitive S. aureus (110) with FICI values 
between 0.28- 0.5. Vancomycin can also synergise with ceftaroline, cefazolin, cefepime 
and nafcillin against MRSA (111). Both of these studies were conducted similarly to our 
study using the FICI to determine whether synergy occurred and following the CLSI 
guidelines. Although both studies used Mueller Hinton Broth rather than RPMI-1640 + 
5% LB broth which was used in our study. Vancomycin can also synergise with 
trimethoprim to combat wild type E. coli isolates. The MIC for vancomycin alone against 
E. coli was 400 µg/mL, which supported our research with MIC for E. coli predominantly 
>300 µg/mL (the highest concentration that we tested). When vancomycin was combined 
with trimethoprim, the MIC concentration of vancomycin decreased to 50 µg/mL for one 
E. coli isolate and 8 µg/mL for the other E. coli isolate. This finding shows a lesser marked 
effect, when compared to our study, as when vancomycin synergised with the IDR1018 
there was a 125 fold decrease in the concentration of vancomycin required to inhibit the 
growth of bacteria. This suggests that IDR1018 is a better candidate for synergy with 




Synergy has also been investigated between other antimicrobial peptides and antibiotics 
in several studies. A study by (101) showed synergy can occur between the human 
cathelicidins LL-37 and azithromycin against multidrug resistant K. pneumoniae, A. 
baumannii and P. aeruginosa. This study was performed similarly to our study using 
RPMI-1640 + 5% LB broth. IDR1018 is derived from a bovine form of LL-37 and is 
similar in structure, suggesting that IDR1018 might also synergise with azithromycin. 
LL-37 has also been shown to synergise with antibiotics ceftriaxone and ciprofloxacin 
against Salmonella enterica serotype Newport strains in RPMI-1640 + 10% LB and 
cation adjusted Mueller-Hinton broth, consistent with our results for E. coli. In contrast 
to our findings with IDR1018, no synergy was found with the murine cathelicidins 
(CRAMP) and vancomycin against S. typhimurium (112). Although there were additive 
effects similar to the additive effects we recorded from IDR1018 and vancomycin against 
E. faecium VRE there was no synergy, with the FICI equal to 0.57 which is just over the 
threshold for synergy. This study used Mueller Hinton broth as its medium, in comparison 
with RPMI-1640 which was used in our study and those with LL-37. As stated earlier, it 
has been suggested that eukaryotic cell media may provide a more effective means for 
determining bactericidal activity under more physiologically-relevant conditions (101).  
 
In comparison to the combination of IDR1018 and vancomycin, which synergised against 
Gram negative E. coli, none of the Gram positive isolates showed synergy with IDR1018 
and gentamicin or vancomycin. Instead, vancomycin was effective on its own and didn’t 
become more effective when combined with IDR018.  Futures studies to determine this 
mechanism of action could use confocal and fluorescent microscopy to determine how 
IDR1018 is entering the cell to further understand how IDR1018 and vancomycin interact 
for gram negative killing. We attempted to use fluorescence microscopy to determine this 
  
mode of action although the procedure used was unsuccessful and the results were 
inconclusive.  
 
The above findings partly support the first part of our hypothesis, that IDR1018 can 
combine synergistically with commonly used neonatal antibiotics to target neonatal 
pathogens. When synergy occurs between IDR1018 and vancomycin, the concentration 
of each drug required to kill E. coli decreases significantly. Target trough levels in 
neonates are typically aimed to be below 25 µg/mL as vancomycin is nephrotoxic in high 
concentrations (57). At the synergistic concentration, vancomycin is at 2.4 µg/mL which 
would cause much less concern regarding nephrotoxicity for the infant as this dose is ~10 
fold lower than the maximum target trough level.  This synergistic combination has a 
broad range of activity, as it can kill both Gram positive and negative organisms. This is 
ideal for empirical therapy for neonatal therapy, when treatment is given without knowing 
what the causative pathogen is.   
 
4.3 Effectiveness of combined doses of IDR1018 and vancomycin in human 
serum  
The synergistic combination of vancomycin and IDR1018 had reduced activity in the 
presence of pooled human serum. The combination still had bactericidal activity against 
E. coli, but only reduced the CFU/mL of E. coli by 2 logs, compared to the current 
recommended therapy for neonatal sepsis - combined gentamicin and vancomycin - 
which decreased CFU/mL to below the lower limit of detection. Against S. aureus, the 
synergistic combination’s CFU/mL decreased below the lower limit of detection at the 
same curve as vancomycin alone, suggesting that vancomycin was active in the 
combination whereas IDR1018 was not. Additionally, vancomycin alone at 300 µg/mL 
  
had activity against E. coli, decreasing the CFU/mL by 1 log, although in the MIC 
experiments vancomycin had an MIC of >300 µg/mL against the same strain of E. coli.  
 
Although there have been no studies to our knowledge that have looked at a decrease of 
antimicrobial activity by IDR1018 when in human serum, there have been multiple 
studies investigating impediments to the systemic activity of antimicrobial peptides. A 
study by Svenson, et al. investigated the interactions between 9 cationic antimicrobial 
peptides in both human and bovine serum (113) against S. aureus. The outcome of this 
study suggested that all of the antimicrobial peptides tested bound to albumin, and were 
unable to combat the bacteria. This binding lowered the effective concentration of 
antimicrobial peptides available in the solution to inhibit or kill the S. aureus (113). This 
result is consistent with our project, where IDR1018 was less able to combat the bacteria 
in serum when compared to MICs. This could possibly be due to binding to a protein in 
the serum such as albumin, described in the study above, although further research would 
be required to determine this binding.  
 
Another study by Starr, et al. had similar results to our project. This study incubated 
cationic antimicrobial peptides in different percentages of serum to determine the MIC of 
those peptides against E. coli and S. aureus (114). The MIC for antimicrobial peptide 
melittin against E. coli with no serum was ~2 uM, whereas when 20% serum was added, 
the MIC against E. coli increased 9 fold to ~18 uM. The study suggests that weak host 
cell binding may account for the inhibition of antimicrobial peptide activity. These results 
also support the findings in our study, that antimicrobial peptides in serum are not as 
effective at lower concentrations.  
 
  
The same study by Hyonmin et, al that demonstrated comparable MICs to ours against S. 
aureus in vitro, also tested IDR1018 against S. aureus in vivo to determine whether 
IDR1018 decreases the infection in orthopaedic implants in mice. IDR1018 was tested at 
a concentration of 1 mg/mL, and was found to only partially reduce the bacterial burden 
of S. aureus in mice, suggesting host factors limiting effectiveness  (108).  
 
If IDR1018 is limited by serum protein binding, one possible way to overcome the 
inhibition, would be to increase the concentration of the antimicrobial peptide, to allow 
for the loss of active AMP due to binding to albumin or similar proteins. Although 
clinically, increasing the concentration of IDR1018 causes the potential for toxicity to the 
neonate. Additionally, increasing the concentration of IDR1018 would cause this therapy 
to become more expensive.  Another possible solution to serum protein binding would be 
to limit or inhibit the binding protein in the serum, after determining the causative protein.  
 
An alternate explanation for the lack of synergy between IDR1018 and vancomycin in 
human serum may be due to antagonism/competition between endogenous AMPs that 
were already in the pooled serum and IDR1018.  In support of this, I found that 
vancomycin worked at a lower concentration in pooled serum than in the microdilution 
plates 2.4 µg/mL vs >300 µg/mL, consistent with endogenous AMP activity. This could 
be LL-37, given the similarity with IDR1018 . Lin et. al showed using fluorescence 
microscopy that LL-37 is able to enter the cell when synergised with antibiotic 
azithromycin (101). It is possible that LL-37 is entering the E. coli bacterial cells in my 
serum experiments and blocking IDR1018 from entering the cell. Mansour et al. showed 
that IDR1018 has more killing activity than both the parent molecule and endogenous 
LL-37 (8). Consequently, if LL-37 is entering the bacterial cell before IDR1018, there 
would be decreased level of bactericidal activity, as shown in the time-to-kill curve, 
  
although currently there is no published evidence to support this claim. This could be 
investigated by fluorescence microscopy, to identify which AMP is entering the bacterial 
cells.  
 
IDR1018 has also previously been tested in vivo against a S. aureus isolates in terms of 
wound healing in porcine models (115). Skin wounds were made on the back of two pigs 
and inoculated with S. aureus. Wounds were treated topically with IDR1018 and assessed 
for re-epithelialisation. It was found that re-epithelisation was most effective at a high 
dose of IDR1018 at 200 µg/mL.  IDR1018 only had a partial response in vivo during this 
study, which again suggests that  IDR1018 may possibly be inhibited by an endogenous 
component inside the serum, although further research is required to confirm this.  
 
4.3 Heating serum Prior to Using in Time-to-kill Assay  
The synergy between IDR1018 and vancomycin was restored by heat treatment of the 
pooled human serum. In an attempt to combat the suspected binding interactions between 
the serum and IDR1018, the serum was heated to 70ºC for 10 minutes before the time-to-
kill assay was repeated. Heat was used to denature the proteins in the serum to prevent 
any suspected binding from occurring. Once the serum had been heated, the time-to-kill 
experiment was repeated using the IDR1018/vancomycin combination and using no drug 
as a control against E. coli. IDR1018/vancomycin inhibited bacterial colonies more 
rapidly when serum has been heated, when compared to unheated serum. This suggests 
that there is a heat labile component of the serum that is inhibiting IDR1018.  
 
Additionally, the CFU/mL of the no drug treatment was much higher at 24 hours with 
heat killed serum, when compared to the CFU/mL of the no drug treatment with normal 
serum. At 24 hours the CFU/mL had increased by 6 logs in the heat killed serum, while 
  
the CFU /mL at 24 hours for the normal serum was only 2 logs higher . This would support 
the hypothesis that there may be endogenous AMPs, such as LL-37, in the pooled serum 
which are working against the bacteria. These AMPs are likely to be heat sensitive and 
therefore would be killed during the heating of the serum which allowed the bacteria to 
grow uninhibited over the 24 hour time period, although little research has examined the 
heat sensitivity of cathelicidins.  
 
The results determined from heating the serum prior to running the time-to-kill assay 
supports multiple hypothesis stated above. Heating the serum, before addition of 
IDR0118, could denature the endogenous LL-37, decreasing competition with the sub-
optimal competitor which would allow IDR1018 to move into the bacterial cell. As 
IDR1018 has better bactericidal properties when compared to LL-37, the rate of killing 
would be increased, as seen in Figure 3.3, where the synergistic combination of IDR1018 
and vancomycin decreased the CFU/mL rapidly when in serum that had been heated. 
Alternatively, heating the serum would also denature heat labile proteins such as albumin, 
which may be binding to the IDR1018 and preventing enough being active in solution. 
To test these two hypotheses, the AMPs in the blood would need to be identified, possibly 
by using mass spectrometry and examine the interactions between the identified AMPs 
and IDR1018 or by removing proteins such as albumin from the serum and attempting 
the time-to-kill experiments again.  
By removing the potential for albumin or another protein binding with the peptide or 
endogenous AMPs entering bacterial cells first, the synergistic combination would have 





A few limitations of our study could be identified. The first major limitation was that S. 
epidermidis, the predominant pathogen in LOS, was unable to grow in RPMI-1640 + 5% 
LB in small volumes such as 100 µL, which caused the change from S. epidermidis to S. 
aureus. It would be important to determine which component of RPMI-1640 + 5% LB 
was inhibiting growth of S. epidermidis, or find an alternate growth medium in future 
studies, so that the synergy with IDR1018 and vancomycin can be tested.  
 
Another limitation was due to limited volumes of human serum that could be obtained. 
Only 5mL of whole blood was available from each volunteer, ~2.5mL of which could be 
converted into serum. As serum was restricted in volume, not all isolates could be tested 
in the time-to-kill assay and minimal repeats were possible. E. coli ATCC25922 and S. 
aureus ATCC29213 were chosen to use in the Time Kill assay as they are prominent 
pathogens causing neonatal sepsis. Due to extremely limited volumes, only E. coli 
ATCC25922 was used in the time-to-kill using heat treated serum. E. coli ATCC25922 
was chosen as this was the pathogen that IDR1018 and vancomycin synergised against. 
In future studies, it would be important to perform the time-to-kill assay using 
vancomycin resistant pathogens using normal and heat treated serum. Another limitation 
that we experienced was only using adult serum in our project, which may differ from 
neonatal blood. Neonates, especially those born preterm have significantly less 
endogenous AMPs in their blood compared with adults (116), therefore IDR1018 would 
have less competition with other AMPs in neonates and would likely have better 
antimicrobial activity. Due to time constraints, we had a small sample size of isolates and 
bacterial species with only one Gram negative pathogen (E. coli). In future studies it 
would be valuable to test other Gram negative bacterial pathogens, as well as other 
glycopeptides such as teicoplanin or telavancin.  
  
4.5 Conclusions and Future Directions 
In summary, this study assessed the activity of IDR1018 in inhibiting or killing common 
neonatal pathogens E. coli, S. aureus, E. faecalis and E. faecium. We found that doses of 
≤15 µg/mL were an effective monotherapy under standard testing conditions. This 
finding means that IDR1018 is a potential broad-spectrum therapy. We also assessed the 
interaction between IDR1018 and vancomycin. When vancomycin is tested in 
monotherapy, it has limited activity against E. coli. We found that IDR1018 and 
vancomycin can synergise against E. coli and show additive activity against all other 
tested neonatal pathogens under standard CLSI testing conditions. The effectiveness of 
this synergistic combination was assessed in adult pooled serum. We found that IDR1018 
and vancomycin had reduced activity against both E. coli and S. aureus with no synergy 
was detected, and found that synergy was recovered when the pooled serum was heated 
prior to use. These findings supported our first hypothesis, that IDR1018 can combine 
synergistically with neonatal antibiotics to more rapidly inhibit both Gram negative and 
positive neonatal pathogens under standard testing conditions. The findings, when using 
the heat-treated serum, also supported our second hypothesis, that the optimal 
combination found above will inhibit or kill neonatal pathogens in human adult blood 
(serum).  
 
In principle, AMPs may be an effective empirical therapy, but there are clearly challenges 
when translating this therapy in vivo. There are physiological conditions that will limit 
the use of AMPs, as shown in this study. Studies should be done to look at natural levels 
of AMP in individuals, both adults and neonates to determine the possible activity 
occurring between IDR1018 and AMPs in physiological conditions. Studies should also 
be completed to quantify and compare the levels of AMPs in adult plasma compared to 
neonates. To determine whether IDR1018 and vancomycin would be a viable option as a 
  
therapy for neonatal sepsis, studies must look at effective delivery and dosing rates, and 
best combination concentrations of the drugs in vivo, possibly using relevant animal 
models.  
 
Based on these findings, future works should measure the levels of endogenous AMPS 
in individual serum in both neonatal serum and adult serum in individual samples. .It 
would also be valuable to measure and quantify the levels of endogenous AMPs in adult 
serum when compared to neonatal serum, as this area is relatively unknown. These 
findings would assist in determining the effectiveness of this drug combination in 
neonates from the adult blood model.  
 
Overall, our novel study looking at neonatal isolates with vancomycin or gentamicin 
against IDR1018 has provided valuable information into the synergistic properties of the 
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